Literature DB >> 19410314

Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis.

Niclas Pettersson1, Jan Nyman, Karl-Axel Johansson.   

Abstract

BACKGROUND AND
PURPOSE: The aim of this study is to analyse the dose-response and the volume-response of radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy (SBRT).
MATERIALS AND METHODS: During the period 1998-2005, 68 patients with medically inoperable stage I non-small cell lung cancer (NSCLC) were treated with hypofractionated SBRT to 45 Gy in 3 fractions. Among the 33 patients with complete treatment records and radiographic follow-up exceeding 15 months (median: 29 months), 13 fractures were found in seven patients. Identifying all ribs receiving at least 21 Gy, 81 ribs (13 with and 68 without fracture) in 26 patients were separately contoured and their dose-volume histograms (DVHs) were obtained. The DVHs were assessed with the mean dose and cut-off models. Maximum likelihood estimation was used to fit dose-response and volume-response curves to each model.
RESULTS: It was possible to quantify the risk of radiation-induced rib fracture using response curves and information contained in the DVHs. Absolute volumes provided better fits than relative volumes and dose-response curves were more suitable than volume-response curves. For the dose given by the 2 cm(3) cut-off volume, D(2 cm(3)), the logistic dose-response curve for three fractions was parameterised by D(50)=49.8 Gy and gamma(50)=2.05. Consequently, for a median follow-up of 29 months, if D(2 cm(3))<3 x 7.0 Gy the risk is close to 0, and the 5% and 50% risks are given by D(2 cm(3))=3 x 9.1 Gy and 3 x 16.6 Gy, respectively.
CONCLUSIONS: In this group of patients, the risk for radiation-induced rib fracture following hypofractionated SBRT was related to the dose to 2 cm(3) of the rib.

Entities:  

Mesh:

Year:  2009        PMID: 19410314     DOI: 10.1016/j.radonc.2009.03.022

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  47 in total

Review 1.  The role of stereotactic body radiotherapy in the management of non-small cell lung cancer: an emerging standard for the medically inoperable patient?

Authors:  Gregory M M Videtic; Kevin L Stephans
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

Review 2.  Alternatives to surgery for early stage non-small cell lung cancer-ready for prime time?

Authors:  Millie Das; Mohamed H K Abdelmaksoud; Billy W Loo; Nishita Kothary
Journal:  Curr Treat Options Oncol       Date:  2010-06

3.  Stereotactic body radiotherapy for stage I non-small cell lung cancer.

Authors:  Ben J Slotman
Journal:  J Radiosurg SBRT       Date:  2011

4.  Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer.

Authors:  Robert W Mutter; Fan Liu; Andres Abreu; Ellen Yorke; Andrew Jackson; Kenneth E Rosenzweig
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-08-23       Impact factor: 7.038

Review 5.  Stereotactic body radiation therapy: a novel treatment modality.

Authors:  Simon S Lo; Achilles J Fakiris; Eric L Chang; Nina A Mayr; Jian Z Wang; Lech Papiez; Bin S Teh; Ronald C McGarry; Higinia R Cardenes; Robert D Timmerman
Journal:  Nat Rev Clin Oncol       Date:  2009-12-08       Impact factor: 66.675

Review 6.  Radiobiology of stereotactic body radiation therapy (SBRT).

Authors:  Miquel Macià I Garau
Journal:  Rep Pract Oncol Radiother       Date:  2017-03-23

7.  A dosimetric parameter to limit chest wall toxicity in SABR of NSCLC.

Authors:  Raphaël Jumeau; Édith Filion; Houda Bahig; Toni Vu; Louise Lambert; David Roberge; Robert Doucet; Marie-Pierre Campeau
Journal:  Br J Radiol       Date:  2017-06-07       Impact factor: 3.039

8.  Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer.

Authors:  J Martin Brown; Maximilian Diehn; Billy W Loo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-01       Impact factor: 7.038

9.  Bone scan findings of chest wall pain syndrome after stereotactic body radiation therapy: implications for the pathophysiology of the syndrome.

Authors:  Shane Lloyd; Roy H Decker; Suzanne B Evans
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

Review 10.  Role of stereotactic body radiotherapy in spinal metastasis and subsequent fracture risk: identifying and treating the at-risk patient.

Authors:  Mekhail Anwar; Igor J Barani
Journal:  CNS Oncol       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.